CureVac raises 27.6 million euros
Tübingen — German mRNA vaccine specialist CureVac GmbH has secured a 27.6 million euro financing round with Dievini Hopp BioTech Holding. The company has announced that it will use the proceeds to drive forward its programmes for RNActive therapeutic vaccines against solid tumours, and to accelerate the development of prophylactic vaccines against infectious diseases. CureVac’s lead compound for prostate cancer, CV9103, is in a Phase IIa trial, with results expected in the second half of 2010. The company is developing CV9201, an mRNA vaccine compound to treat non-small cell lung cancer (NSCLC), in a separate Phase I study.